US OptionsDetailed Quotes
NVS241220P95000
- 0.11
- 0.000.00%
15min DelayClose Dec 3 16:00 ET
0.00High0.00Low
0.11Open0.11Pre Close0 Volume895 Open Interest95.00Strike Price0.00Turnover26.42%IV9.25%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.11Extrinsic Value100Contract SizeAmericanOptions Type-0.0405Delta0.0146Gamma1045.60Leverage Ratio-0.0144Theta-0.0018Rho-42.38Eff Leverage0.0196Vega
Novartis AG Stock Discussion
Sign in to post a comment
Morning Movers
Gapping up
$Deere (DE.US)$ 's stock rose by 1.6% following their announcement of fourth-quarter earnings that surpassed analyst forecasts, despite substantial market hurdles.
Cryptocurrency-related stocks experienced a widespread surge. $MicroStrategy (MSTR.US)$ saw a significant increase, jumping over 13%, while $MARA Holdings (MARA.US)$ climbed more than 11%.
$Snowflake (SNOW.US)$ 's shares surged 23.3% as ...
Gapping up
$Deere (DE.US)$ 's stock rose by 1.6% following their announcement of fourth-quarter earnings that surpassed analyst forecasts, despite substantial market hurdles.
Cryptocurrency-related stocks experienced a widespread surge. $MicroStrategy (MSTR.US)$ saw a significant increase, jumping over 13%, while $MARA Holdings (MARA.US)$ climbed more than 11%.
$Snowflake (SNOW.US)$ 's shares surged 23.3% as ...
27
5
10
This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...
+18
15
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary...
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary...
+18
25
1
$Novartis AG (NVS.US)$ Why it keeps dropping ? didn't see any bad news
1
$Esperion Therapeutics (ESPR.US)$ The recent analyst note from Jeff sugest Esperion might sell the entire rights for Bempedoic Acid. Fair valuation on the rights would be above $1.5 billion, based on future milestones $900 million, future royalties & patents, the current formulation patent has exp date Dec 2031. The potential yearly sales in the U.S could reach $4 billion by 2027.
Esperion could also partner in the U.S .
Keep an...
Esperion could also partner in the U.S .
Keep an...
1
1
Haha... a good start! I never been good with trading, will see how this end ![]()
3
The Federal Reserve on Wednesday implemented its first rate cut in over four years, reducing the benchmark rate by 50 basis points to a range of 4.75%-5%.
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
+7
75
9
84
Morning Movers
Gapping up
$Williams-Sonoma (WSM.US)$ The home furnishing company saw its shares increase by 2.8% following an upgrade from Jefferies to 'buy' from 'hold.' Jefferies highlighted "hidden gems" in the company's portfolio that could benefit from even a modest recovery in the housing market.
$Viking Therapeutics (VKTX.US)$ Shares of the biotech company soared more than 4.2% as JPMorgan initiated coverage with an 'overweight'...
Gapping up
$Williams-Sonoma (WSM.US)$ The home furnishing company saw its shares increase by 2.8% following an upgrade from Jefferies to 'buy' from 'hold.' Jefferies highlighted "hidden gems" in the company's portfolio that could benefit from even a modest recovery in the housing market.
$Viking Therapeutics (VKTX.US)$ Shares of the biotech company soared more than 4.2% as JPMorgan initiated coverage with an 'overweight'...
31
1
4
No comment yet
103827296 : Halo Medan hai hai English understand I'm sorry
72627089 : fractional shares
72627089 : would like to chat about fractional shares
(R-long)103834298 : stop all
l0lBElBgG : k